Alto Neuroscience Inc (ANRO)

$11.00 -0.18 (-1.61%)
Market Cap 302.72M
Revenue (ttm) 0.00
Net Income (ttm) -61.43M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.16
Volume 356,500
Avg Vol 1,813,698
Day's Range N/A - N/A
Shares Out 27.08M
Stochastic %K 83%
Beta 2.00
Analysts Strong Sell
Price Target $13.00

Company Profile

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule ph...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 200 0412
Address:
650 Castro Street, Suite 450, Mountain View, United States
BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:23 PM
$ANEW $ANF $ANGO $ANIP $ANRO
0 · Reply
MOOSEN
MOOSEN Oct. 24 at 5:48 PM
$SLS MOVING MORE $ANRO OVER.
0 · Reply
MOOSEN
MOOSEN Oct. 24 at 12:55 PM
$ANRO
0 · Reply
Stef_DL
Stef_DL Oct. 24 at 11:37 AM
$ANRO Nice 😁.
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 10:26 AM
HC Wainwright & Co. has updated their rating for Alto Neuroscience ( $ANRO ) to Buy with a price target of 50.
0 · Reply
Ccperk
Ccperk Oct. 24 at 10:24 AM
$ANRO OMG 😳 a $50 but rating just came out
0 · Reply
MOOSEN
MOOSEN Oct. 23 at 11:17 PM
$ANRO HOW IS THIS ON THE RADAR SLIGHT?
0 · Reply
MOOSEN
MOOSEN Oct. 23 at 9:12 PM
$ANRO KEEP ON, BIG BOY.
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Oct. 23 at 7:42 PM
$ANRO beauty ..stair pattern ..we know where it is going
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:50 PM
$ANGO $ANIP $ANRO 🔥 Cycle Trading Signal plugged into AI 🔥 You lie they lie but Math don't lie 🔥 keep counting 😉
0 · Reply
Latest News on ANRO
Alto Neuroscience Announces $50 Million Private Placement Financing

Oct 20, 2025, 7:03 AM EDT - 5 days ago

Alto Neuroscience Announces $50 Million Private Placement Financing

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Oct 20, 2025, 7:01 AM EDT - 5 days ago

Alto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA Meeting

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 8, 2025, 9:56 AM EDT - 16 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Oct 3, 2025, 10:51 AM EDT - 21 days ago

Johnson Fistel, PLLP Investigates Claims on Behalf of Alto Neuroscience, Inc. Long-Term Shareholders

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

Oct 3, 2025, 7:34 AM EDT - 22 days ago

Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Sep 13, 2025, 11:50 AM EDT - 5 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

Sep 9, 2025, 7:09 AM EDT - 6 weeks ago

Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 28, 2025, 5:40 PM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Aug 22, 2025, 10:15 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto Neuroscience

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

Aug 18, 2025, 9:45 AM EDT - 2 months ago

Lawsuit DEADLINE: Investors who purchased over $100,000 worth of shares of Alto Neuroscience, Inc. (NYSE: ANRO) between Feb. and Oct. 2024 should contact the Shareholders Foundation

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Aug 18, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANRO

Alto Neuroscience to Participate in Upcoming Investor Conferences

Aug 18, 2025, 8:03 AM EDT - 2 months ago

Alto Neuroscience to Participate in Upcoming Investor Conferences

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Aug 13, 2025, 4:10 PM EDT - 2 months ago

Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Aug 13, 2025, 8:03 AM EDT - 2 months ago

Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

Aug 4, 2025, 2:46 PM EDT - 2 months ago

Alto Neuroscience, Inc. Investigated for Breaches of Fiduciary Duty - Contact the DJS Law Group to Discuss Your Rights – ANRO

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 22, 2025, 6:25 PM EDT - 3 months ago

ALTO NEUROSCIENCE, INC. (NYSE: ANRO) INVESTOR ALERT Investors With Large Losses in Alto Neuroscience, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Jun 30, 2025, 8:03 AM EDT - 4 months ago

Alto Neuroscience Highlights Peer-Reviewed Publication of PAX-D Study in The Lancet Psychiatry Demonstrating Robust Clinical Effects of Pramipexole for Patients with Treatment-Resistant Depression

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Jun 26, 2025, 7:33 AM EDT - 4 months ago

Alto Neuroscience Identifies Biomarker and Reports Positive Pharmacodynamic Results from Exploratory Phase 2 Proof-of-Concept Trial of ALTO-203

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Jun 3, 2025, 6:03 AM EDT - 5 months ago

Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

May 29, 2025, 8:03 AM EDT - 5 months ago

Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 14, 2025, 4:10 PM EDT - 5 months ago

Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Apr 28, 2025, 8:03 AM EDT - 6 months ago

Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Apr 22, 2025, 8:03 AM EDT - 6 months ago

Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

Mar 20, 2025, 4:10 PM EDT - 7 months ago

Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 8 months ago

The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Feb 19, 2025, 8:03 AM EST - 8 months ago

Alto Neuroscience Announces U.S. Patent Granted Covering ALTO-300 as a Treatment for Patients with Major Depressive Disorder Characterized by an Electroencephalogram Biomarker

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

Feb 12, 2025, 8:03 AM EST - 9 months ago

Alto Neuroscience Announces Favorable Outcome from Interim Analysis of ALTO-300 Phase 2b Major Depressive Disorder Trial

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

Feb 2, 2025, 11:00 AM EST - 9 months ago

The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Alto Neuroscience, Inc. For Securities Fraud

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

Jan 27, 2025, 11:15 AM EST - 9 months ago

The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Investigation Into Alto Neuroscience, Inc.

BEATOFtheMARKET
BEATOFtheMARKET Oct. 24 at 10:23 PM
$ANEW $ANF $ANGO $ANIP $ANRO
0 · Reply
MOOSEN
MOOSEN Oct. 24 at 5:48 PM
$SLS MOVING MORE $ANRO OVER.
0 · Reply
MOOSEN
MOOSEN Oct. 24 at 12:55 PM
$ANRO
0 · Reply
Stef_DL
Stef_DL Oct. 24 at 11:37 AM
$ANRO Nice 😁.
0 · Reply
JarvisFlow
JarvisFlow Oct. 24 at 10:26 AM
HC Wainwright & Co. has updated their rating for Alto Neuroscience ( $ANRO ) to Buy with a price target of 50.
0 · Reply
Ccperk
Ccperk Oct. 24 at 10:24 AM
$ANRO OMG 😳 a $50 but rating just came out
0 · Reply
MOOSEN
MOOSEN Oct. 23 at 11:17 PM
$ANRO HOW IS THIS ON THE RADAR SLIGHT?
0 · Reply
MOOSEN
MOOSEN Oct. 23 at 9:12 PM
$ANRO KEEP ON, BIG BOY.
0 · Reply
RoaringSwissKitty
RoaringSwissKitty Oct. 23 at 7:42 PM
$ANRO beauty ..stair pattern ..we know where it is going
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Oct. 23 at 6:50 PM
$ANGO $ANIP $ANRO 🔥 Cycle Trading Signal plugged into AI 🔥 You lie they lie but Math don't lie 🔥 keep counting 😉
0 · Reply
Ccperk
Ccperk Oct. 22 at 12:39 AM
$ANRO lot of puts at 7.5 but lot of calls at 12.5 lol. Doesn’t matter cuz I’m holding long term. I wasn’t expecting a price like this until 2026/7.
0 · Reply
MACnTEEZ
MACnTEEZ Oct. 21 at 10:34 PM
$ANRO come over to BGIN new ipo and slap the ask!
0 · Reply
stockfan567
stockfan567 Oct. 21 at 9:45 PM
$ANRO likely another stock which will get dumped in the near future... poor continuation today. Just another biotech which crashes after one day of hype.
0 · Reply
MOOSEN
MOOSEN Oct. 21 at 5:28 PM
$ANRO STIIIILLLLLLL.
0 · Reply
rick_b
rick_b Oct. 21 at 4:25 PM
$ANRO Easy money. Here we go. Send it!
0 · Reply
rick_b
rick_b Oct. 21 at 3:29 PM
$ANRO Get ready! This pump is about to melt faces. Send it!
0 · Reply
rick_b
rick_b Oct. 21 at 2:15 PM
$ANRO Coiling up for another pump. Send it!
0 · Reply
Godwins26
Godwins26 Oct. 21 at 2:07 PM
$YDKG 1Billion volume to be obtain today 😊 $GSIT $REPL $ANRO $BYND
0 · Reply
QHH
QHH Oct. 21 at 2:01 PM
$ANRO "The most recent analyst rating on ANRO stock is BUY with a $16.00 price target" - Tipranks. com
0 · Reply
Godwins26
Godwins26 Oct. 21 at 12:51 PM
Watchlist for today 😊🚀 $YDKG $GSIT $REPL $ANRO $BYND
0 · Reply
Stef_DL
Stef_DL Oct. 21 at 8:28 AM
$ANRO Nice, i'm up 200% already. Can she hit 400%... 🥰?
0 · Reply
ApeTradez
ApeTradez Oct. 21 at 7:54 AM
$ANRO Keep an eye on VIVK cheap penny name primed for 100% move 🦍🦍
0 · Reply